Michael Keenan, page-5

Agreed and detestable as Keenan is, OSX clearly even still too opaque for these guys above to see why:

“a wealth of experience and knowledge in public policy and corporate governance”

(i.e. still has a load of crony mates in politics in Australia who will open doors for him and OSX)

Meanwhile OSX getting some more important media coverage that went largely ignored:

https://www.bioworld.com/articles/698966-osteopores-3d-regenerative-implants-could-revolutionize-orthopedic-surgery?v=preview

OSX has been poorly managed, but is undeniably growing revenues fast (albeit from a tiny base) with a massive global sales footprint structure comparative to its size (at imposing past expense, but very distinct future benefit if it remains a going concern), and is rather ridiculously valued at $12 million. It was a stock to desperately avoid in 2019/20/21/22. Despite recent Singapore and Chinese public body endorsements, the close the gate after the horse has bolted investors will probably keep it low until it announces undeniable impressive growth in its next quarterly results. It probably wont gain anything in share price until its earnings => accumulate very cheaply and hold knowing its really a risky call option rather than a stock, that could fizzle if poor management continues, or explode if it fulfills its promise.